Generalized Vitiligo Clinical Trial
Official title:
Comparing the Efficacy of VL-UVA1 Versus NB-UVB on Inducing Repigmentation in Subjects With Generalized Vitiligo
NCT number | NCT05238077 |
Other study ID # | 11973 |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | February 26, 2018 |
Est. completion date | June 2, 2020 |
Verified date | February 2022 |
Source | Henry Ford Health System |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
As part of this study, you may have a procedure called phototherapy which involves either VL-UVA or NB-UVB irradiation. NB-UVB phototherapy is not experimental in vitiligo, but use of VL-UVA1 phototherapy in vitiligo is. The purpose of this pilot study is to determine whether VL-UVA1 or NB-UVB phototherapy more efficiently induces repigmentation in patients with generalized vitiligo.
Status | Terminated |
Enrollment | 1 |
Est. completion date | June 2, 2020 |
Est. primary completion date | May 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subjects = 18 years of age with a diagnosis of generalized vitiligo - Subjects on a stable topical/oral regimen for the past 3 months and continuing on a stable regimen - Subjects able to understand the requirements of the study - Subjects able and willing to sign informed consent Exclusion Criteria: - Subjects on photosensitizing medications - Subjects receiving any concurrent phototherapy - Subjects who plan to use tanning parlors or expose themselves to excess sunlight - Subjects with known photosensitivity disorder - Subjects with apparent phototoxicity - Subjects with unstable vitiligo - Subjects currently using bleaching agents - Subjects who are pregnant, lactating, or planning on becoming pregnant - Subjects who in the opinion of the investigator/sub-investigator, are not appropriate candidates for this study |
Country | Name | City | State |
---|---|---|---|
United States | Department of Dermatology, Henry Ford Medical Center, 3031 West Grand Boulevard, | Detroit | Michigan |
Lead Sponsor | Collaborator |
---|---|
Henry Ford Health System |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in depigmentation of vitiligo lesion | Change in pigment will be assessed by colorimetry which measures change in pigment | 13 measurements over 26 visits | |
Primary | Change in melanin content of vitiligo lesion | Change in pigment will be assessed by diffuse reflectance spectroscopy which will measure the melanin content and dyschromia | 13 measurements over 26 visits |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03487042 -
Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo
|
Phase 4 |